Decipher Labs Limited - Due diligence report

A 360° intelligence report on Combat Drugs: trust score, financial health, credit view, compliance, directors, growth and distress signals -…

1986-09-17 Shaikpet, Telangana Active Listed Active Compliant
Share
DL Decipher Labs Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Combat Drugs — 360° Intelligence Report

Generated from MCA filings & public records
68/100
Trust Score
Moderate

Combat Drugs is assessed as Moderate with a Trust Score of 68/100. Combat Drugs is an active public limited indian non-government company incorporated in 1986, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.

Report generated on 18 Jul 2026 from the latest processed filings. Decipher Labs Limited snapshot & full profile →

Financial Health › Neutral
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
68/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
63/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
50/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Consolidated · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.

Charges position: 2 open (42.25 Lakh) · 3 satisfied (1.40 cr).

Banking relationships (from registered charges)
LenderChargesAmount
The Dhanlakshmi Bank Ltd3 48.0 cr
Vijaya Bank1 48.0 cr
Corporation Bank1 48.0 cr
Compliance Score: 63/100 Moderate
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Flagged by authority: BSE.
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
GAYATHRI RAGHURAM 01234567 Director 01/04/2018 6 yrs Approved
SUSHANT MOHAN LAL 01234567 Director 01/04/2018 6 yrs Approved
SONAM JALAN 01234567 Director 01/04/2018 6 yrs Approved
VENKATESWARA RAO GUDIPUDI 01234567 Director 01/04/2018 6 yrs Approved
LAKSHMI VIJAYA NIMMALA 01234567 Director 01/04/2018 6 yrs Approved
JANAKI RAM AJJARAPU 01234567 Director 01/04/2018 6 yrs Approved
Preeti Singh 01234567 Director 01/04/2018 6 yrs Approved
Dalavath Amarsingh 01234567 Director 01/04/2018 6 yrs Approved
  • 8 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
-

Key managerial personnel: SONAM JALAN (CFO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 60
Growth signals & trust indicators
Operating for 39+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
2 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence64/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment56/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 42.25 Lakh already registered.
  • Compliance gaps should be priced into terms.
Investor view50/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
13 Nov 2025
Director appointed
Dalavath Amarsingh (Additional Director)
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
29 Jan 2025
Director appointed
Preeti Singh (Company Secretary)
29 Sep 2023
Director ceased
GAYATHRI RAGHURAM
04 Sep 2023
Director appointed
GAYATHRI RAGHURAM (Director)
11 May 2023
Director ceased
LAKSHMI VIJAYA NIMMALA
Director ceased
MARY VARA PRASAD MUTLURI
14 Feb 2023
Director appointed
LAKSHMI VIJAYA NIMMALA (Director)
Director appointed
JANAKI RAM AJJARAPU (Director)
29 Sep 2022
Director ceased
VENKATESWARA RAO GUDIPUDI
13 Aug 2022
Director appointed
VENKATESWARA RAO GUDIPUDI (Director)
Director ceased
JANAKI RAM AJJARAPU
30 Apr 2022
Director ceased
KUMAR RAGHAVAN
29 Sep 2020
Director ceased
VASUDEV KOMARAJU
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
8 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Swissol Chemicals (India) Private Limited U24100MH1994PTC078863 Mumbai, Maharashtra, India
Cvs Infrastructure Private Limited U29100MH1995PTC090372 Mumbai, Maharashtra, India
Starsource Multitrade Limited L46900MH1942PLC003556 Kalyan, Maharashtra, India
Kabra Drugs L02423MP1989PLC005438 Indore, Madhya Pradesh, India
Mk Aromatics Limited L24231TN1983PLC010417 Alathur, Tamil Nadu, India
Triochem Products Limited L24249MH1972PLC015544 Mumbai, Maharashtra, India
Khoobsurat L23209WB1982PLC034793 Kolkata, West Bengal, India
Doliosis Holistic Medicine And Foods Private Limited U24234MH1997PTC109705 Pune, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Combat Drugs before audits and certifications: compliance score 63/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Combat Drugs: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Combat Drugs - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 68/100, distress signals and MSME payment-delay disclosures - know whether Combat Drugs pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Combat Drugs - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Combat Drugs an active company?

Combat Drugs has MCA status “Active” with a compliance score of 63/100 (Moderate).

Is Combat Drugs financially healthy?

Combat Drugs has a Financial Health Score of 50/100 (Moderate) based on its filed financial statements.

Should I do business with Combat Drugs?

Its overall Trust Score is 68/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Combat Drugs?

See the directors and ownership sections above for board and shareholding detail. 8 active director(s) are on record.

Does Combat Drugs have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Combat Drugs up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 63/100 (Moderate).

Is it risky to lend to Combat Drugs?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.